NZ734379A - 4-substituted benzoxaborole compounds and uses thereof - Google Patents

4-substituted benzoxaborole compounds and uses thereof

Info

Publication number
NZ734379A
NZ734379A NZ734379A NZ73437916A NZ734379A NZ 734379 A NZ734379 A NZ 734379A NZ 734379 A NZ734379 A NZ 734379A NZ 73437916 A NZ73437916 A NZ 73437916A NZ 734379 A NZ734379 A NZ 734379A
Authority
NZ
New Zealand
Prior art keywords
compounds
benzoxaborole compounds
substituted benzoxaborole
ch2ch2ch3
ch2ch3
Prior art date
Application number
NZ734379A
Other languages
English (en)
Inventor
Michael Richard Kevin Alley
Jacob J Plattner
Xianfeng Li
Vincent Hernandez
Carlos Alemparte-Gallardo
David Barros-Aguirre
Ilaria Giordano
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ734379(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of NZ734379A publication Critical patent/NZ734379A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ734379A 2015-02-12 2016-02-12 4-substituted benzoxaborole compounds and uses thereof NZ734379A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15382054 2015-02-12
EP15382055 2015-02-12
EP15382056 2015-02-12
PCT/IB2016/050775 WO2016128948A1 (en) 2015-02-12 2016-02-12 4 -substituted benzoxaborole compounds and uses thereof

Publications (1)

Publication Number Publication Date
NZ734379A true NZ734379A (en) 2023-06-30

Family

ID=55409879

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ734379A NZ734379A (en) 2015-02-12 2016-02-12 4-substituted benzoxaborole compounds and uses thereof

Country Status (36)

Country Link
US (3) US10774096B2 (https=)
EP (2) EP3256479B1 (https=)
JP (2) JP2018506540A (https=)
KR (2) KR20170117158A (https=)
CN (2) CN107548398A (https=)
AU (3) AU2016217508A1 (https=)
BR (2) BR112017017213A2 (https=)
CA (2) CA2976308A1 (https=)
CL (2) CL2017002059A1 (https=)
CO (2) CO2017008809A2 (https=)
CR (2) CR20170371A (https=)
CY (1) CY1123687T1 (https=)
DK (1) DK3256479T3 (https=)
DO (2) DOP2017000188A (https=)
EA (2) EA036516B1 (https=)
ES (1) ES2821951T3 (https=)
HR (1) HRP20201597T1 (https=)
HU (1) HUE051113T2 (https=)
IL (2) IL253865A0 (https=)
LT (1) LT3256479T (https=)
MA (2) MA41494B1 (https=)
MX (2) MX379057B (https=)
MY (1) MY194004A (https=)
NZ (1) NZ734379A (https=)
PE (2) PE20171432A1 (https=)
PH (2) PH12017501427A1 (https=)
PL (1) PL3256479T3 (https=)
PT (1) PT3256479T (https=)
RS (1) RS60885B1 (https=)
SG (2) SG11201706510YA (https=)
SI (1) SI3256479T1 (https=)
SM (1) SMT202000565T1 (https=)
TW (2) TW201702250A (https=)
UA (1) UA120527C2 (https=)
WO (2) WO2016128949A1 (https=)
ZA (1) ZA201705456B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
RS63461B1 (sr) 2017-05-08 2022-08-31 Glaxosmithkline Ip Dev Ltd Sanfetrinem ili njegova so ili estar za upotrebu u lečenju mikobakterijske infekcije
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
WO2020041200A1 (en) 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
EP4384527A4 (en) * 2022-06-23 2025-09-03 Micurx Pharmaceuticals Inc PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
CA3239096A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
EP0947498B1 (en) 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
EP2343304B1 (en) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
EP1856113B1 (en) 2005-03-08 2016-01-06 Agency for Science, Technology and Research Chiral bisoxazoline catalysts
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010080558A1 (en) 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
ES2710105T3 (es) * 2010-04-07 2019-04-23 Glaxosmithkline Llc Proceso para preparar benzoxaboroles
SI3251678T1 (sl) * 2010-09-07 2022-01-31 Anacor Pharmaceuticals, Inc. Derivati benzoksaborola za zdravljenje bakterijskih okužb
JP6031122B2 (ja) * 2011-12-22 2016-11-24 ミクウルク ファーマシューティカルズ,インコーポレイテッド 抗微生物療法のための三環式ホウ素化合物
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof

Also Published As

Publication number Publication date
US10774096B2 (en) 2020-09-15
TW201643173A (zh) 2016-12-16
DOP2017000189A (es) 2018-02-15
WO2016128948A1 (en) 2016-08-18
CN107531730A (zh) 2018-01-02
CL2017002059A1 (es) 2018-03-16
EP3256480A1 (en) 2017-12-20
SG11201706511TA (en) 2017-09-28
US20180044353A1 (en) 2018-02-15
PH12017501428A1 (en) 2018-01-15
DOP2017000188A (es) 2017-09-15
IL253864A0 (en) 2017-09-28
AU2016217508A1 (en) 2017-09-28
HRP20201597T1 (hr) 2020-12-25
LT3256479T (lt) 2020-12-28
BR112017017213A2 (pt) 2018-04-03
AU2016217507B2 (en) 2019-03-14
BR112017017211A2 (pt) 2018-04-03
RS60885B1 (sr) 2020-11-30
US20180037595A1 (en) 2018-02-08
MX2017010414A (es) 2018-05-11
SMT202000565T1 (it) 2020-11-10
CR20170372A (es) 2017-10-19
IL253865A0 (en) 2017-10-31
EP3256479B1 (en) 2020-07-29
PL3256479T3 (pl) 2021-06-14
DK3256479T3 (da) 2020-11-02
KR20170117158A (ko) 2017-10-20
CL2017002060A1 (es) 2018-03-16
CA2976030A1 (en) 2016-08-18
CY1123687T1 (el) 2022-03-24
SG11201706510YA (en) 2017-09-28
EA201791671A1 (ru) 2018-02-28
JP2018506540A (ja) 2018-03-08
EA036516B1 (ru) 2020-11-18
MA41495A (fr) 2017-12-19
PE20171432A1 (es) 2017-09-26
AU2016217507A1 (en) 2017-09-28
CN107531730B (zh) 2020-08-07
TWI730953B (zh) 2021-06-21
CN107548398A (zh) 2018-01-05
EP3256479A1 (en) 2017-12-20
US11214582B2 (en) 2022-01-04
JP2018506538A (ja) 2018-03-08
MA41494B1 (fr) 2020-10-28
EA201791667A1 (ru) 2018-02-28
US20210053996A1 (en) 2021-02-25
MX379057B (es) 2025-03-10
MY194004A (en) 2022-11-07
HUE051113T2 (hu) 2021-01-28
ZA201705456B (en) 2019-10-30
CR20170371A (es) 2018-01-22
MA41494A (fr) 2017-12-19
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
WO2016128949A1 (en) 2016-08-18
CO2017008816A2 (es) 2017-11-10
AU2020256369A1 (en) 2020-11-12
JP6771472B2 (ja) 2020-10-21
TW201702250A (zh) 2017-01-16
BR112017017211B1 (pt) 2023-04-25
IL253864B (en) 2021-07-29
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
CO2017008809A2 (es) 2017-11-10
CA2976308A1 (en) 2016-08-18
PE20171348A1 (es) 2017-09-13
PH12017501427A1 (en) 2018-01-15
CA2976030C (en) 2023-09-26
ES2821951T3 (es) 2021-04-28
KR20170117156A (ko) 2017-10-20

Similar Documents

Publication Publication Date Title
PH12017501428A1 (en) 4-substituted benzoxaborole compounds and uses thereof
CR20210083A (es) Compuestos de anillo fusionado
EA201490357A1 (ru) Индазолы
PH12016500234A1 (en) Tricyclic benzoxaborole compounds and uses thereof
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
MX2018003781A (es) Compuestos semifluorados para administracion oftalmica.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX382665B (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
PH12016501440A1 (en) Novel heterocyclic compounds
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MX379459B (es) Inhibidores de bromodominios.
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed